Selvadurai Muralidharan, Kalaimani Jaya Raja Kumar

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Improving Candidate Quality Through the Prediction of Clinical Outcome.
Nomenclature: Every drug has three names: 1) Chemical Name:  The drug is named according to its chemical structure. 2) Generic name (common name): 
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Pharmacokinetics & Pharmacodynamics of Controlled Release Systems Presented By: Govardhan.P Dept. of pharmaceutics, University College of Pharmaceutical.
“FUTURE CONSIDERATIONS FOR PK/PD RESEARCH” Terrence F. Blaschke, M.D. Professor of Medicine and Molecular Pharmacology Stanford University.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
Modeling Systems and Processes Anthony McGoron, PhD Associate Professor Department of Biomedical Engineering Florida International University.
PHARMACEUTICAL INDUSTRY Drug Discovery - natural sources, synthesis/modification Preclinical Studies biological properties - pharmacology, pharmacokinetics.
Clinical Pharmacy Part 2
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
Pharmacokinetics Introduction
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
FARMAKOKINETIKA. INTRODUCTION Historically, pharmaceutical scientists have evaluated the relative drug availability to the body in vivo after giving a.
Basic Pharmacokinetics The time course of drug action Collected and Prepared By S.Bohlooli, PhD.
Touqeer Ahmed Ph.D. Atta-ur-Rahman School of Applied Bioscience, National University of Sciences and Technology 21 st October, 2013.
Biopharmaceutics refers to the relationship of the:
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
1 Controlled drug release Dr Mohammad Issa. 2 Frequency of dosing and therapeutic index  Therapeutic index (TI) is described as the ratio of the maximum.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
The General Concepts of Pharmacokinetics and Pharmacodynamics
Clinical Pharmacokinetics Fundamental hypothesis: a relationship exists between the pharmacological or toxic response to a drug and the accessible concentration.
INTRODUCTION CLINICAL PHARMACOKINETICS
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Introduction to Pharmacology Yacoub Irshaid MD, PhD, ABCP Department of Pharmacology.
Principles of Drug Action
PHT 415 BASIC PHARMACOKINETICS
The General Concepts of Pharmacokinetics and Pharmacodynamics
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
Foundation Knowledge and Skills
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
In vitro - In vivo Correlation
Pharmacokienetic Principles (2): Distribution of Drugs
Chemistry 301 Q1 September 14, 2017: Agenda
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
Introduction of Biopharmaceutics & Pharmacokinetics
Dissolution testing and in vitro in vivo correlation of conventional and SR preparations Formulation development and optimization is an ongoing process.
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
The 3-compartment pharmacokinetic model
Controlled drug release
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Quantitative Pharmacokinetics
Distribution of protein therapeutics
Pharmaceutics 2.
Pharmacokinetics and Pharmacodynamics of Peptide and Protein Drugs
Pharmacokinetics: Drug Distribution and Drug Reservoirs
Biopharmaceutics Dr Mohammad Issa Saleh.
Pharmacokinetics: Drug Distribution and Drug Reservoirs
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
Clinical Pharmacokinetics
PHT 612 Selected Topics in Drug Delivery I
1 Concentration-time curve
Chapter 1 Introduction of Pharmacology [,fɑ:mə'kɔlədʒi] 药理学
Therapeutic Drug Monitoring chapter 1 part 1
Pharmacokinetics and Pharmacodynamics of Peptide and Protein Drugs
Introduction to Pharmacology
Lecture-7 Pharmaceutical Biotechnology
Introduction to Pharmacology
Clinical Pharmacokinetics
FDA Drug Approval Process
Distribution of protein therapeutics
Introduction to Pharmacogenetics
Introduction to Pharmacology
Presentation transcript:

Selvadurai Muralidharan, Kalaimani Jaya Raja Kumar The Importance of Pharmacokinetic and Pharmacodynamic Models in Sustained Release Formulation Selvadurai Muralidharan, Kalaimani Jaya Raja Kumar

The main role of preclinical pharmacokinetics and pharmacodynamics in drug discovery and development is to optimize candidate selection for the target therapeutic area, taking into consideration the type of agent required, and to predict the dose and dosing regimen for initial clinical trials with due concern to the requirements for effective treatment in the target therapeutic area. In order for this approach to be successful, a clear understanding is required for both the pharmacological target and drug disposition (absorption, clearance and distribution) of new chemical entities. A fundamental tenet in linking the pharmacokinetic and pharmacodynamic phases is that free drug in the systemic circulation is in equilibrium with the receptors. In the pharmacokinetic phase, only free drug can be cleared and drug is reversibly bound to tissues and blood.  

The pharmacodynamic phase is further subdivided into the interaction with the drug receptor triggering postreceptor events, eventually leading to actual drug effect. In this phase, only free drug can exert pharmacological effect and the free concentration of drug in plasma is in direct equilibrium with the interstitial fluid bathing most cells, since the capillary wall contains sufficient aqueous pores to allow the rapid passage of relatively small molecules, regardless of physicochemistry. Most receptor targets are accessed extracellularly. Therefore, one can expect that all drugs regardless of physicochemistry will be in direct equilibrium, at these targets, with free drug in plasma.

KEYWORDS Bioavailability, Drug discovery, Formulations, PK-PD models, Sustained release dosage form.

PK-PD modeling has emerged as a major tool in clinical pharmacology to optimize drug use by designing rational dosage forms and dosage regimes. Quantitative representation of the dose–concentration–response relationship should provide information for prediction of the level of response to a certain level of drug dose. Several mathematical approaches can be used to describe such relationships, depending on the single dose or the steady-state measurements carried out. The development of a correlation is based on the scientific principles associated with mathematical modeling, statistical evaluation, and numerical deconvolution. The development and validation of a PK/PD is based on the ability of fraction of the drug absorbed versus fraction of the drug-dissolved relationship of various formulations.